floxuridine has been researched along with Disease Exacerbation in 18 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin in advanced previously untreated colorectal cancer." | 9.12 | A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| "Concurrent carboplatin chemotherapy did not significantly improve the long-term survival after inductive carboplatin and floxuridine chemotherapy in locoregionally advanced nasopharyngeal carcinoma." | 5.20 | Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. ( Cao, KJ; Guo, L; Guo, X; Hong, MH; Huang, PY; Mai, HQ; Mo, HY; Qian, CN; Wu, PH; Zeng, Q, 2015) |
| "Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin in advanced previously untreated colorectal cancer." | 5.12 | A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| "Advanced prostate cancer, which is one of the most common cancers, usually progresses to hormone-refractory prostate cancer (HRPC)." | 2.73 | Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. ( Honda, J; Kai, N; Kikuchi, K; Kikukawa, H; Kuwahara, T; Matsumoto, K; Nakanishi, J; Takahashi, W; Ueda, S; Wada, Y, 2008) |
| "Sixty gastric cancer patients were divided randomly into three groups (20 each group) before operation: group one:5'-DFUR oral administration at the dose of 800-1200 mg/d for 3 - 5 d, group two: 500 mg 5-FU + 200 mg/d CF by venous drip for 3 - 5 d,group three (control group)." | 2.72 | Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action. ( Ding, W; Luo, B; Ma, ZM; Sheng, JM; Teng, LS; Wang, M; Wang, SF; Wu, FS; Zhao, WH, 2006) |
| "47%, P = 0." | 2.70 | Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. ( Anderson, J; Burton, M; Gebski, V; Gray, B; Hope, M; Moroz, P; Van Hazel, G, 2001) |
| "Median times to disease progression for the three treatment arms were as follows: 9." | 2.69 | Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000) |
| "Analysis of 98 colorectal cancers revealed that PyNPase was as high as 70." | 2.40 | [PyNPase expression and cancer progression in the colorectum]. ( Amano, M; Haba, A; Ikeda, K; Izawa, H; Kanoh, T; Monden, M; Monden, T; Ohnishi, T; Okamura, J; Sekimoro, M; Tomita, N; Tsujie, M, 1998) |
| "Animals with pancreatic cancer displayed focal uptake of both tracers." | 1.31 | In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. ( Glatting, G; Greten, FR; Neumaier, B; Reske, SN; Schmid, RM; Seitz, U; Vogg, AT; Wagner, M, 2001) |
| "Doxifluridine (5-DFUR) is an orally active fluoropyrimidine, and its cytotoxic metabolite (5-FU) may concentrate in areas of high tumor vascularization." | 1.30 | Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. ( Artale, S; Bajetta, E; Bozzetti, F; Buzzoni, R; Di Bartolomeo, M; Mazzaferro, V; Ricci, SB; Stani, SC; Toffolatti, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 13 (72.22) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, PY | 1 |
| Zeng, Q | 1 |
| Cao, KJ | 1 |
| Guo, X | 1 |
| Guo, L | 1 |
| Mo, HY | 1 |
| Wu, PH | 1 |
| Qian, CN | 1 |
| Mai, HQ | 1 |
| Hong, MH | 1 |
| Wagner, PL | 1 |
| Jones, D | 1 |
| Aronova, A | 1 |
| Shia, J | 1 |
| Weiser, MR | 1 |
| Temple, LK | 1 |
| Chung, KY | 1 |
| O'Reilly, EM | 1 |
| Kelsen, D | 1 |
| Paty, PB | 1 |
| Nash, GM | 1 |
| Terashima, M | 1 |
| Fujiwara, H | 1 |
| Takagane, A | 1 |
| Abe, K | 1 |
| Araya, M | 1 |
| Irinoda, T | 1 |
| Yonezawa, H | 1 |
| Nakaya, T | 1 |
| Oyama, K | 1 |
| Takahashi, M | 1 |
| Saito, K | 1 |
| Alimonti, A | 1 |
| Ferretti, G | 1 |
| Di Cosimo, S | 1 |
| Cognetti, F | 1 |
| Vecchione, A | 1 |
| Zhao, WH | 1 |
| Wang, SF | 1 |
| Ding, W | 1 |
| Sheng, JM | 1 |
| Ma, ZM | 1 |
| Teng, LS | 1 |
| Wang, M | 1 |
| Wu, FS | 1 |
| Luo, B | 1 |
| Gore, ME | 1 |
| Escudier, B | 1 |
| Wada, Y | 1 |
| Kikuchi, K | 1 |
| Takahashi, W | 1 |
| Honda, J | 1 |
| Nakanishi, J | 1 |
| Matsumoto, K | 1 |
| Kuwahara, T | 1 |
| Kai, N | 1 |
| Kikukawa, H | 1 |
| Ueda, S | 1 |
| Ardalan, B | 1 |
| Kozyreva, O | 1 |
| Tsai, KT | 1 |
| Santos, E | 1 |
| Franceschi, D | 1 |
| Livingstone, A | 1 |
| Lima, M | 1 |
| Muggia, FM | 1 |
| Jeffers, S | 1 |
| Muderspach, L | 1 |
| Roman, L | 1 |
| Rosales, R | 1 |
| Groshen, S | 1 |
| Safra, T | 1 |
| Morrow, CP | 1 |
| Monden, T | 1 |
| Haba, A | 1 |
| Amano, M | 1 |
| Kanoh, T | 1 |
| Tsujie, M | 1 |
| Ikeda, K | 1 |
| Izawa, H | 1 |
| Ohnishi, T | 1 |
| Sekimoro, M | 1 |
| Tomita, N | 1 |
| Okamura, J | 1 |
| Monden, M | 1 |
| Bajetta, E | 1 |
| Di Bartolomeo, M | 1 |
| Stani, SC | 1 |
| Artale, S | 1 |
| Ricci, SB | 1 |
| Bozzetti, F | 1 |
| Mazzaferro, V | 1 |
| Toffolatti, L | 1 |
| Buzzoni, R | 1 |
| Lorenz, M | 1 |
| Müller, HH | 1 |
| Dawson, LA | 1 |
| McGinn, CJ | 1 |
| Normolle, D | 1 |
| Ten Haken, RK | 1 |
| Walker, S | 1 |
| Ensminger, W | 1 |
| Lawrence, TS | 1 |
| Takahashi, Y | 1 |
| Mai, M | 1 |
| Taguchi, T | 1 |
| Urushizaki, I | 1 |
| Nishioka, K | 1 |
| Allen-Mersh, TG | 1 |
| Glover, C | 1 |
| Fordy, C | 1 |
| Mathur, P | 1 |
| Quinn, H | 1 |
| De Larco, JE | 1 |
| Wuertz, BR | 1 |
| Manivel, JC | 1 |
| Furcht, LT | 1 |
| Seitz, U | 1 |
| Wagner, M | 1 |
| Vogg, AT | 1 |
| Glatting, G | 1 |
| Neumaier, B | 1 |
| Greten, FR | 1 |
| Schmid, RM | 1 |
| Reske, SN | 1 |
| Gray, B | 1 |
| Van Hazel, G | 1 |
| Hope, M | 1 |
| Burton, M | 1 |
| Moroz, P | 1 |
| Anderson, J | 1 |
| Gebski, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Phase III Randomized Trial of Standard Dose Stereotactic Body Radiation Therapy (SBRT) Versus Radiobiologically-Guided Dose Selected SBRT In Primary or Secondary Liver Carcinoma (SAVIOR).[NCT04745390] | 110 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
| Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957] | 180 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for floxuridine and Disease Exacerbation
| Article | Year |
|---|---|
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II | 2006 |
[PyNPase expression and cancer progression in the colorectum].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Colorectal Neoplasms; Disease Progressi | 1998 |
9 trials available for floxuridine and Disease Exacerbation
| Article | Year |
|---|---|
Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy, Ad | 2015 |
Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2006 |
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Pro | 2008 |
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2007 |
Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbop | 1997 |
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neopl | 2000 |
Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Di | 2001 |
7 other studies available for floxuridine and Disease Exacerbation
| Article | Year |
|---|---|
Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2012 |
Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); | 2002 |
Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Floxuridine; Fluorouraci | 2003 |
Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Feasi | 1999 |
Prolonged stable disease effects survival in patients with solid gastric tumor: analysis of phase II studies of doxifluridine.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Disease Progression; Floxuridin | 2000 |
Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Divisi | 2001 |
In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model.
Topics: Animals; Cell Division; Disease Models, Animal; Disease Progression; Floxuridine; Fluorodeoxyglucose | 2001 |